Pyrrolidine dithiocarbamate down-regulates vascular matrix metalloproteinases and ameliorates vascular dysfunction and remodelling in renovascular hypertension.
about
Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological targetConstrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetesVitamin D induces increased systolic arterial pressure via vascular reactivity and mechanical properties.Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathyThe role of reactive oxygen species in microvascular remodeling.Atorvastatin and sildenafil decrease vascular TGF-β levels and MMP-2 activity and ameliorate arterial remodeling in a model of renovascular hypertensionAtorvastatin and sildenafil lower blood pressure and improve endothelial dysfunction, but only atorvastatin increases vascular stores of nitric oxide in hypertension.Matrix metalloproteinases are involved in cardiovascular diseases.Novel intracellular N-terminal truncated matrix metalloproteinase-2 isoform in skeletal muscle ischemia-reperfusion injury.Protective activity of gallic acid against glyoxal -induced renal fibrosis in experimental rats.Antioxidant effect of doxycycline decreases MMP activity and blood pressure in SHR.Experimental and clinical findings regarding matrix metalloproteinases in cardiovascular diseases.The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase-2 Up-Regulation in Renovascular Hypertension.Nitric oxide attenuates matrix metalloproteinase-9 production by endothelial cells independent of cGMP- or NFκB-mediated mechanisms.Sodium nitrite attenuates MMP-9 production by endothelial cells and may explain similar effects of atorvastatin.Combined Aliskiren and L-arginine treatment reverses renovascular hypertension in an animal model.
P2860
Q26864722-0C0679E7-6F69-4258-971B-04E633D908AAQ28081462-0BD78C8A-E632-4740-8E7E-1889A21A7402Q33748607-0ED044D8-972D-45C3-95D8-A0E5D831E9DAQ34067504-05537206-B941-48B9-B9C9-2479AF68D850Q34836065-C5AF9B1B-8378-4E1E-8EB9-67BC32794A10Q36042695-51182570-BA0F-451C-B2E6-B836C19FB22CQ37393748-32E19020-9A5D-4D5D-9741-B7FFBD2FABADQ38224193-89FDEAD6-2C0B-455E-A626-F3C4CE0A6B59Q38849042-26EBE7B4-F556-4125-88F0-0937BA17EDA1Q41680141-0CD6A44C-87F7-4B7D-AB3D-D5C2AF2C3B76Q43538572-7280C20D-1DD1-48F4-A405-E73580ED705EQ44391648-5162B1AC-E365-475D-8C22-6A4841D8D180Q46752526-20636920-4C97-44B1-A955-89D985286175Q51827526-333BF921-D3BA-4A8C-8243-B55EC67B53E6Q53261742-ED0B224A-F4EB-417D-8A3E-93E67496663CQ53594610-35F105D5-DF30-430F-B8EF-A03E210F4BA4
P2860
Pyrrolidine dithiocarbamate down-regulates vascular matrix metalloproteinases and ameliorates vascular dysfunction and remodelling in renovascular hypertension.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Pyrrolidine dithiocarbamate do ...... in renovascular hypertension.
@ast
Pyrrolidine dithiocarbamate do ...... in renovascular hypertension.
@en
type
label
Pyrrolidine dithiocarbamate do ...... in renovascular hypertension.
@ast
Pyrrolidine dithiocarbamate do ...... in renovascular hypertension.
@en
prefLabel
Pyrrolidine dithiocarbamate do ...... in renovascular hypertension.
@ast
Pyrrolidine dithiocarbamate do ...... in renovascular hypertension.
@en
P2093
P2860
P1476
Pyrrolidine dithiocarbamate do ...... in renovascular hypertension.
@en
P2093
C R Tirapelli
D A Guimaraes
J E Tanus-Santos
R F Gerlach
P2860
P304
P356
10.1111/J.1476-5381.2011.01360.X
P407
P577
2011-09-01T00:00:00Z